Cancer Family
Melanocytic Neoplasm
CI-CAN-00000026Explore in graph →
Non-malignant610 active trials13 approved drugs233 evidence items
- NCIt
- C7058
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000026Explore in graph →
Clinical trials
3,258 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06751524 | Expanded Access Program (EAP) Designed to Provide Access to Botensilimab and Balstilimab Before Regulatory Approval | available | — | — | Agenus Inc.INDUSTRY | 0 | May 15, 2026 | clinicaltrials |
| NCT06889766 | NY-ESO-1-redirected T Cells in Patients With Advanced Melanoma and Sarcoma(LauT1) | recruiting | Phase 1 | 9 | Centre Hospitalier Universitaire VaudoisOTHER | 1 | May 15, 2026 |
| NCT06594991 | A Study of Fianlimab, Cemiplimab, and Ipilimumab in People With Melanoma | recruiting | Phase 2 | 88 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT07581509 | Pharmacokinetics, Safety, and Immunogenicity of Bmab1800 and Keytruda® as Adjuvant Monotherapy in Patients With Melanoma | not yet recruiting | Phase 1 | 138 | Biocon Biologics UK PLCINDUSTRY | 0 | May 14, 2026 | clinicaltrials |
| NCT07586904 | Efficacy and Safety of Neoadjuvant Cadonilimab Plus High-Dose Recombinant Human Interferon α1b in Stage III/IV Melanoma. | recruiting | Early Phase 1 | 10 | Xijing HospitalOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT03420508 | Treating Patients With Melanoma and ALK Alterations With Ensartinib | active not recruiting | Phase 2 | 18 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT04314401 | National Cancer Institute "Cancer Moonshot Biobank" | active not recruiting | — | 1,600 | National Cancer Institute (NCI)NIH | 2 | May 13, 2026 | clinicaltrials |
| NCT04640545 | A Study to Assess LBL-007 in Combination With Toripalimab and Axitinib Tablets Subjects With Advanced Melanoma | completed | Phase 1 | 79 | Nanjing Leads Biolabs Co.,LtdINDUSTRY | 1 | May 13, 2026 | clinicaltrials |
| NCT07584291 | Liquid Biopsy Multi-Omics and Biomarker Development in Melanoma | recruiting | — | 200 | Xijing HospitalOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT02437227 | Dose Escalation Study With Expansion to Evaluate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of CCT3833(PanRAF) | completed | Phase 1 | 31 | Royal Marsden NHS Foundation TrustOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT05492682 | START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer | recruiting | Phase 1 | 15 | Valo Therapeutics OyINDUSTRY | 2 | May 12, 2026 | clinicaltrials |
| NCT05645510 | LIVInG With chrONic Cancer TrEatments (LONGEVITI) Study(LONGEVITI) | recruiting | — | 75 | University of AlbertaOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT05661955 | A Study to Investigate the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of BGB-A445 in Combination With Tislelizumab in Participants With Select Advanced Solid Tumors. | active not recruiting | Phase 1 / Phase 2 | 113 | BeiGeneINDUSTRY | 1 | May 11, 2026 | clinicaltrials |
| NCT04146064 | Breathomics as Predictive Biomarker for Checkpoint Inhibitor Response | completed | — | 190 | University Health Network, TorontoOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT06697301 | Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma. | recruiting | Phase 2 / Phase 3 | 740 | Eikon TherapeuticsINDUSTRY | 24 | May 8, 2026 | clinicaltrials |
| NCT06870487 | A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers | terminated | Phase 1 | 6 | PfizerINDUSTRY | 2 | May 8, 2026 | clinicaltrials |
| NCT03552718 | QUILT-2.025 NANT Neoepitope Yeast Vaccine (YE-NEO-001): Adjuvant Immunotherapy Using a Personalized Neoepitope Yeast-Based Vaccine To Induce T-Cell Responses In Subjects W/ Previously Treated Cancers. | completed | Phase 1 | 5 | NantBioScience, Inc.INDUSTRY | 1 | May 7, 2026 | clinicaltrials |
| NCT04726319 | Family History App in Personalized Medicine(FHAMe) | completed | N/A | 627 | University of TorontoOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT04728633 | Transarterial Chemoembolization for the Treatment of Uveal Melanoma With Liver Metastases | active not recruiting | Phase 2 | 28 | Thomas Jefferson UniversityOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT07015190 | Neoadjuvant Darovasertib in Primary Uveal Melanoma | recruiting | Phase 3 | 520 | IDEAYA BiosciencesINDUSTRY | 21 | May 6, 2026 | clinicaltrials |
| NCT07444606 | Dose Ranging, Toxicity Seeking, Phase 1 Trial of Oncolytic Adenoviral Therapy for Melanoma Intracranial and Extracranial Metastases | not yet recruiting | Phase 1 | 50 | M.D. Anderson Cancer CenterOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT07555210 | Pilot Study of Bone Mineral Density Changes During Anti-PD-1 Immunotherapy | recruiting | N/A | 25 | Jessica Mezzanotte SharpeOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT04778449 | Quality of Life, Lifestyle, and Psychosocial Factors in Patients With Melanoma | recruiting | — | 5,000 | M.D. Anderson Cancer CenterOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT07564570 | Physical Activity Directly Before Immunotherapy (Nivolumab and Ipilimumab) in Melanoma(SPRINT) | recruiting | N/A | 40 | Universitätsklinikum Hamburg-EppendorfOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT06463509 | Establishment and Standardization of a Platform for In-depth Tumour Profiling (TUPRO) in Patients With Melanoma(TUPRO) | completed | — | 116 | Reinhard DummerOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT04902040 | Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies | terminated | Phase 1 / Phase 2 | 19 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT06151847 | Lifileucel With Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion and Interleukin-2 for the Treatment of Patients With Unresectable or Metastatic Melanoma | completed | Phase 2 | 11 | University of Kansas Medical CenterOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT04483778 | B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults | active not recruiting | Phase 1 | 68 | Seattle Children's HospitalOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT06413680 | A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body(BrILliance) | recruiting | Phase 1 / Phase 2 | 240 | Regeneron PharmaceuticalsINDUSTRY | 1 | Apr 28, 2026 | clinicaltrials |
| NCT02279004 | A Prospective Study of Plasma Genotyping as a Noninvasive Biomarker for Genotype-directed Cancer Care | active not recruiting | — | 840 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 27, 2026 | clinicaltrials |
| NCT05421988 | Effectiveness of Group and Individual Training in EFT for Patients in Remission From Melanoma | completed | N/A | 56 | Soul Medicine InstituteOTHER | 1 | Apr 27, 2026 | clinicaltrials |
| NCT05522660 | Immunotherapy or Targeted Therapy With or Without Stereotactic Radiosurgery for Patients With Brain Metastases From Melanoma or Non-small Cell Lung Cancer(USZ-STRIKE) | recruiting | Phase 3 | 180 | ETOP IBCSG Partners FoundationNETWORK | 5 | Apr 27, 2026 | clinicaltrials |
| NCT07552467 | Sub-topic Four: Clinical Translation of Original Radioactive Drugs for Precision Diagnosis and Treatment of Gastrointestinal Tumors -Clinical Application Value of PET Imaging Targeting LRRC15 in Malignant Tumors | recruiting | — | 26 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Apr 27, 2026 | clinicaltrials |
| NCT01416831 | Comparison of High-dose IL-2 and High-dose IL-2 With Radiation Therapy in Patients With Metastatic Melanoma.(SBRT/IL-2) | active not recruiting | Phase 2 | 44 | Providence Health & ServicesOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT06246227 | ctDNA for Early Detection of Recurrence in Melanoma | active not recruiting | — | 467 | Herlev and Gentofte HospitalOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT06919809 | Effectiveness and Safety of X A-DERM™ Microsurfaced Acellular Dermal Matrix for Wound Healing After MOHS Surgery | completed | N/A | 16 | McGuire InstituteINDUSTRY | 1 | Apr 24, 2026 | clinicaltrials |
| NCT02562625 | Trial of Pembrolizumab and Radiotherapy in Melanoma(PERM) | terminated | Phase 2 | 17 | Royal Marsden NHS Foundation TrustOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT04207086 | A Phase II Study of Neoadjuvant Pembrolizumab & Lenvatinib for Resectable Stage III Melanoma(Neo PeLe) | active not recruiting | Phase 2 | 21 | Melanoma Institute AustraliaOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT04759781 | MElanoma Research Lymph Node Prediction Implementation National_001(MERLIN_001) | active not recruiting | — | 1,820 | SkylineDxINDUSTRY | 1 | Apr 23, 2026 | clinicaltrials |
| NCT05187884 | Neoadjuvant/Adjuvant Trial of Darovasertib in Ocular Melanoma(NADOM) | completed | Phase 2 | 15 | St Vincent's Hospital, SydneyOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT05341349 | Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-200M for the Treatment of Melanoma Brain Metastases | terminated | Phase 1 | 1 | Emory UniversityOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT06974734 | A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic Malignancies | terminated | Phase 1 | 8 | PfizerINDUSTRY | 2 | Apr 23, 2026 | clinicaltrials |
| NCT07203391 | Tebentafusp and Roginolisib in Uveal Melanoma to Prolong T-cell Homeostasis(TRIUMPH) | recruiting | Phase 1 | 8 | St Vincent's Hospital, SydneyOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT05352672 | Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma | active not recruiting | Phase 3 | 1,546 | Regeneron PharmaceuticalsINDUSTRY | 24 | Apr 22, 2026 | clinicaltrials |
| NCT06624644 | A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma | recruiting | Phase 2 / Phase 3 | 135 | Linnaeus Therapeutics, Inc.INDUSTRY | 1 | Apr 22, 2026 | clinicaltrials |
| NCT01590069 | Aerosolized Aldesleukin in Treating Patients With Lung Metastases | active not recruiting | Phase 1 | 70 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 21, 2026 | clinicaltrials |
| NCT01604889 | A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma | terminated | Phase 1 / Phase 2 | 50 | Incyte CorporationINDUSTRY | 1 | Apr 21, 2026 | clinicaltrials |
| NCT01682083 | Dabrafenib With Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma (COMBI-AD).(COMBI-AD) | completed | Phase 3 | 870 | Novartis PharmaceuticalsINDUSTRY | 25 | Apr 21, 2026 | clinicaltrials |
| NCT07092410 | Surgical or Radiotherapeutic Intervention Concerning Large Singular Stable to Progressive Metastases in Patients With BRAFV600-mutated Melanoma Receiving Treatment With Encorafenib + Binimetinib(SuRage-EB) | withdrawn | Phase 4 | 0 | SRH Wald-Klinikum Gera GmbHOTHER | 0 | Apr 21, 2026 | clinicaltrials |
Data updated 23 days agoSource updated May 15, 2026source: clinicaltrials